Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$125,000.00

A microfluidic platform for personalized throughput drug screening using cancer spheroids

FY 2018-19

Summary
Cancer remains the leading cause of death worldwide. For many patients, standard-of-care therapy involves surgical removal of the primary tumour, however the surgery is often followed by the growth of secondary microtumours at distant locations. Therapies are required that are either toxic toward micrometastases or that lock them in the dormant state, yet there is a challenge to assess the effectiveness of drugs for microtumors grown in different environments with varying protective properties. * Currently, there is lack of tools that recreate micrometastasis for the evaluation of therapeutic agents. Animal models are expensive, labor- and time-consuming; generally, provide only endpoint analyses and arguably, are not relevant for humans. Two-dimensional cell culture yields microtumor models that differ considerably in their properties and phenotype from those grown in physiological 3D environments, and thus may not serve as an efficient model for drug screening. Multicellular cancer spheroids (MCS) bridge 2D cell culture and animal models, and have very promising applications in drug screening however presently used MCS models for drug screening suffer from a number of limitations. * This proposal aims at the development of a microfluidic (MF) platform for screening of new drugs and optimization of existing drug formulations for therapeutic cancer treatment. The technology utilizes large arrays of uniformly-sized MCSs derived from patient-derived cells that are grown in a biomimetic hydrogel in a MF device, the delivery of drugs to these MCSs under close-to-physiological flow conditions, and throughput screening of drug efficacy for MCS treatment. The MF-MCS platform includes multiple parallel rows of microwells, with up to 100 MCSs in each row. The platform enables systematic variation of a particular factor between different rows, thus enabling screening of drug efficacy for MCSs grown from a particular cell type in a specific environment, and the effect of drug dosages and combinations, to name just a few, all in one series of experiments conducted in a single MF device. *
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
530375-2018
Name nom
Kumacheva, Eugenia
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Partie
1
Nb partie
1
Application title
A microfluidic platform for personalized throughput drug screening using cancer spheroids
Keyword
NSERC
Application summary
Cancer remains the leading cause of death worldwide. For many patients, standard-of-care therapy involves surgical removal of the primary tumour, however the surgery is often followed by the growth of secondary microtumours at distant locations. Therapies are required that are either toxic toward micrometastases or that lock them in the dormant state, yet there is a challenge to assess the effectiveness of drugs for microtumors grown in different environments with varying protective properties. * Currently, there is lack of tools that recreate micrometastasis for the evaluation of therapeutic agents. Animal models are expensive, labor- and time-consuming; generally, provide only endpoint analyses and arguably, are not relevant for humans. Two-dimensional cell culture yields microtumor models that differ considerably in their properties and phenotype from those grown in physiological 3D environments, and thus may not serve as an efficient model for drug screening. Multicellular cancer spheroids (MCS) bridge 2D cell culture and animal models, and have very promising applications in drug screening however presently used MCS models for drug screening suffer from a number of limitations. * This proposal aims at the development of a microfluidic (MF) platform for screening of new drugs and optimization of existing drug formulations for therapeutic cancer treatment. The technology utilizes large arrays of uniformly-sized MCSs derived from patient-derived cells that are grown in a biomimetic hydrogel in a MF device, the delivery of drugs to these MCSs under close-to-physiological flow conditions, and throughput screening of drug efficacy for MCS treatment. The MF-MCS platform includes multiple parallel rows of microwells, with up to 100 MCSs in each row. The platform enables systematic variation of a particular factor between different rows, thus enabling screening of drug efficacy for MCSs grown from a particular cell type in a specific environment, and the effect of drug dosages and combinations, to name just a few, all in one series of experiments conducted in a single MF device. *